

## ASX ANNOUNCEMENT

21 August 2025



# Retirement of director and withdrawal of resolutions

Little Green Pharma Ltd (ASX:LGP) ("**LGP**" or the "**Company**") advises that Mr David Fenlon will retire from the Board due to personal reasons and other commitments at the Company's upcoming Annual General Meeting ("AGM") to be held virtually today, 21 August 2025 at 3:30pm (AWST).

The Company acknowledges and thanks Mr Fenlon for his time and contribution as a Director. The Board is grateful for Mr Fenlon's support and professionalism and wish him every success in his future endeavours.

The Board of Directors has determined that, as a result of Mr Fenlon's retirement as a Director of the Company, it is appropriate to withdraw Resolution 4 (Election of Director – David Fenlon) and Resolution 9(c) (Approval of Issue of up to 150,000 Non-Executive Retention Rights to David Fenlon (or his nominees)).

The withdrawal of Resolutions 4 and 9(c) will not affect the validity of the proxy form in connection with the AGM or any proxy already submitted in respect of the remaining items of business. All other items of business included in the Notice of AGM provided to shareholders will be put to shareholders at the AGM.

Following the AGM, an Appendix 3Z – Final Director's Interest Notice for Mr David Fenlon will be announced by the Company.

**ENDS**

**BY ORDER OF THE BOARD**

A stylized, handwritten signature in black ink, appearing to read "Alistair Warren".

**Alistair Warren**

Company Secretary

For further information please contact:

**Alistair Warren**  
**Company Secretary**

Little Green Pharma  
E: [cosec@lgp.global](mailto:cosec@lgp.global)  
T: +61 8 6280 0050

**Paul Long**  
**Managing Director**

Little Green Pharma  
E: [p.long@lgp.global](mailto:p.long@lgp.global)  
T: +61 8 6280 0050



## About Little Green Pharma

Little Green Pharma Ltd (ASX:LGP) is a leading global medicinal cannabis company with vertically integrated operations across Europe and Australia.

LGP has a diverse and growing portfolio of cannabis-based medicines, distributed across Australia and over 12 export markets via a network of wholesalers, pharmacies, clinics, and GPs. The Company generates revenue through both the sale of medicinal cannabis products and its domestic Health House distribution business, which allows it to capture value across the supply chain and to adapt to evolving regulatory environments while building defensible commercial positions in high-growth markets.

Operating three production facilities in Denmark and Australia – including the largest facility in Europe – LGP is the one of the top three suppliers in Australia, the largest supplier into France, and a significant supplier into Germany and the UK, positioning it as a key player in global medicinal cannabis markets.

With diversified revenue streams, a presence in over a dozen export markets, and a high net tangible asset position relative to its enterprise value, LGP offers investors leveraged exposure to global medicinal cannabis demand and a clear platform for scalable growth.

For more information about Little Green Pharma go to: [www.littlegreenpharma.com](http://www.littlegreenpharma.com)

## Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email to help reduce our costs and environmental footprint.

To easily update your communication preferences, visit: [www.computershare.com.au/easyupdate/lgp](http://www.computershare.com.au/easyupdate/lgp)

## LGP's Cannabis Wrap

LGP's Cannabis Wrap offers insights on global cannabis markets with links to key news and developments from around the world

Sign up to LGP's Cannabis Wrap here: <https://investlittlegreenpharma.com/site/contact/newsletter-sign-up>

Access past Cannabis Wraps here: <https://www.investlittlegreenpharma.com/site/investor-centre/cannabis-industry-wrap>